ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.746,52
0,39%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) News

BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BPMC
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202422h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
31/05/202400h01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
24/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202423h05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
17/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
17/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
15/05/202423h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
15/05/202423h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
10/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202423h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202423h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202422h01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
02/05/202413h00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/04/202414h00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202414h00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
04/04/202422h01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/03/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/03/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/03/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/03/202422h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/03/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
 Showing the most relevant articles for your search:NASDAQ:BPMC

Kürzlich von Ihnen besucht

UNSW
AWFETH
Alpha Wolf
LSE
GOA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten